跳转至内容
Merck
CN

217708

ML141

≥99% (HPLC), solid, Cdc42/Rac1 GTPase inhibitor, Calbiochem®

别名:

Cdc42/Rac1 GTPase Inhibitor, ML141, CDC42 GTPase Inhibitor II, CDC42 Inhibitor II, Rac1 Inhibitor V, Rac1 GTPase Inhibitor II, CID2950007, (±)-4-(5-(4-Methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl))-benzenesulfonamide, (±)-4-(4,5-Dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-pyra, CDC42 GTPase Inhibitor II, CDC42 Inhibitor II, Rac1 Inhibitor V, Rac1 GTPase Inhibitor II, CID2950007, (±)-4-(5-(4-Methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl))-benzenesulfonamide, (±)-4-(4,5-Dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-pyraz

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C22H21N3O3S
化学文摘社编号:
71203-35-5
分子量:
407.49
UNSPSC Code:
12352200
NACRES:
NA.28
MDL number:
MFCD05987165

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Cdc42/Rac1 GTPase Inhibitor, ML141, The Cdc42/Rac1 GTPase Inhibitor, ML141 controls the biological activity of Cdc42/Rac1 GTPase. This small molecule/inhibitor is primarily used for Membrane applications.

InChI

1S/C22H21N3O3S/c1-28-19-11-7-17(8-12-19)22-15-21(16-5-3-2-4-6-16)24-25(22)18-9-13-20(14-10-18)29(23,26)27/h2-14,22H,15H2,1H3,(H2,23,26,27)

InChI key

QBNZBMVRFYREHK-UHFFFAOYSA-N

assay

≥99% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
protect from light

color

yellow-white

solubility

DMSO: 50 mg/mL

shipped in

ambient

storage temp.

−20°C

Quality Level

100

相关类别

Disclaimer

Toxicity: Standard Handling (A)

Other Notes

Hong, L., et al. 2012. J. Biol. Chem.in press.
Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.2010 Feb 27. (http://www.ncbi.nlm.nih.gov/books/NBK51965/)

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

General description

A cell-permeable, allosteric, trisubstituted dihydropyrazolyl compound that acts as a potent, selective, reversible and non-competitive inhibitor of Cdc42 GTPases (IC50 = 0.2, 2.6 and 5.4 µM against nucleotide depleted Cdc42-wt, Cdc42-wt and Cdc42 activated mutant, respectively) with excellent selectivity over Rho family GTPases (IC50 >100 µM for Ras-wt, Ras activated mutant, Rab7-wt, Rab2a-wt, Rac1-wt and Rac1 activated mutant). Shown to efficiently block Cdc42 association with GTPγS and PAK-PBD, and decrease GTP-Cdc42 (>95%) and GTP-Rac1 (≥40%) contents in EGF-stimulated 3T3 cells, and inhibit Bradykinin (Cat. No. . 05-23-0500)-induced filopodia formation in 3T3 cells at 10 µM.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Meiwan Cao et al.
Redox report : communications in free radical research, 27(1), 167-175 (2022-08-09)
The number of neutrophils is significantly reduced in myelodysplastic syndrome (MDS), but the molecular basis remains unclear. We recently found that miR-34a was significantly increased in MDS neutrophils. Therefore, this study aims to clarify the effects of aberrant miR-34a expression
Chang Liu et al.
Acta biomaterialia, 155, 167-181 (2022-11-13)
3D in vitro tumor models have recently been investigated as they can recapitulate key features in the tumor microenvironment. Reconstruction of a biomimetic scaffold is critical in these models. However, most current methods focus on modulating local properties, e.g. micro-
Golnaz Morad et al.
International journal of molecular sciences, 21(11) (2020-06-03)
Breast cancer brain metastasis is a major clinical challenge and is associated with a dismal prognosis. Understanding the mechanisms underlying the early stages of brain metastasis can provide opportunities to develop efficient diagnostics and therapeutics for this significant clinical challenge.
Jun Matsuda et al.
Journal of the American Society of Nephrology : JASN, 31(5), 996-1008 (2020-03-20)
Previous studies showed that Cdc42, a member of the prototypical Rho family of small GTPases and a regulator of the actin cytoskeleton, is critical for the normal development and health of podocytes. However, upstream regulatory mechanisms for Cdc42 activity in

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持